Table 1.
Patient and tumor characteristics
| Variable | No. (%) (n=353) |
|---|---|
| Age (yr) | 47 (23-84) |
| Clinical T category | |
| cT1-2 | 188 (53.3) |
| cT3-4 | 161 (45.6) |
| cTx | 4 (1.1) |
| Nodal involvement | |
| IMN only | 148 (41.9) |
| SCL only | 136 (38.5) |
| SCL+IMN | 69 (19.5) |
| Pathologic T category | |
| ypT0 | 47 (13.3) |
| ypTis | 19 (5.4) |
| ypT1 | 129 (36.5) |
| ypT2 | 87 (24.6) |
| ypT3-4 | 71 (20.1) |
| No. of positive axillary nodes | |
| 0 | 103 (29.2) |
| 1-3 | 98 (27.8) |
| 4-9 | 90 (25.5) |
| ≥ 10 | 62 (17.6) |
| Hormonal receptor status | |
| Positive | 187 (53.0) |
| Negative | 166 (47.0) |
| HER2 status | |
| Positive | 132 (37.4) |
| Negative | 207 (58.6) |
| Equivocal | 14 (4.0) |
| SCL response to NST | |
| Clinical CR | 267 (75.6) |
| Clinical non-CR | 72 (20.4) |
| Unknown | 14 (4.0) |
| IMN response to NST | |
| Clinical CR | 268 (75.9) |
| Clinical non-CR | 66 (18.7) |
| Unknown | 19 (5.4) |
Values are presented as median (range) or number (%).
IMN, internal mammary lymph node; SCL, supraclavicular lymph node; HER2, human epidermal growth factor receptor 2; NST, neoadjuvant systemic therapy; CR, complete remission.